The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease - Concepedia

Concepedia

Publication | Closed Access

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease

66

Citations

43

References

2020

Year

Lingyu Zhang, Yanwei Li, Lin Li, Josefine Ulrikke Melchiorsen, Mette M. Rosenkilde, Christian Hölscher

Journal of Parkinson s Disease

Abstract

The results demonstrate that the DA-CH5 is superior to liraglutide and could be a therapeutic treatment for PD.

References

	Year	Citations
Sydney multicenter study of Parkinson's disease: Non‐<scp>L</scp>‐dopa–responsive problems dominate at 15 years M. A. Hely, John G. Morris, Wayne G.J. Reid, Movement Disorders	2004	1K
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial Dilan Athauda, Kate Maclagan, Simon S. Skene, The Lancet Psychotropic MedicationClinical TrialsPsychopharmacologyNeuropharmacologyWeekly Versus Placebo	2017	811
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Juan P. Frías, Michael A. Nauck, Joanna Van, The Lancet Metabolic SyndromeDiabetes ManagementDiabetesPharmacologyType 2	2018	762
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans Brian Finan, Tao Ma, Nickki Ottaway, Science Translational Medicine	2013	657
Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease Honglei Chen, E. J. O'Reilly, Michael A. Schwarzschild, American Journal of Epidemiology ImmunologyOther Inflammatory BiomarkersNeurochemical BiomarkersNeuroinflammationInflammation	2007	309
Cytokines in Parkinson’s disease Toshiharu Nagatsu, Makio Mogi, Hiroshi Ichinose,	2000	307
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Journal of Neuroinflammation	2008	281
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease Sehee Kim, Minho Moon, Seungjoon Park Journal of Endocrinology	2009	262
Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati, JAMA Neurology	2019	244
Structure−Activity and Protraction Relationship of Long-Acting Glucagon-like Peptide-1 Derivatives: Importance of Fatty Acid Length, Polarity, and Bulkiness Kjeld Madsen, Lotte Bjerre Knudsen, Henrik Agersoe, Journal of Medicinal Chemistry	2007	239

Page 1